New service leverages Company’s extensive expertise in investigator payment processing, innovative cloud payment technology through Medidata and builds on extensive FSP capabilities
Raleigh, N.C. - INC Research Holdings, Inc., a leading global Phase I to IV contract research organization, today announced expansion of its Functional Service Provider (FSP) service offering to include investigator payment processing, leveraging the Company’s extensive expertise and delivery of customized solutions in this area as well as insights gained from its industry-recognized site relationships. The addition of investigator payment processing to the Company’s FSP offering builds on its nearly 20 years of experience in meeting the needs of biopharmaceutical customers worldwide for standalone outsourced services under an FSP model, including Data Management, Medical Writing, Safety and Pharmacovigilance, and Site Contracts.
“INC’s long history in working under the FSP business model, along with our proven track record in delivery of customized payment processing solutions for clinical research sites, are combining to create an exciting new offering for our customers,” said Tara Fitzgerald, President, Clinical Development Services and Head of the Company’s FSP offering. “We look forward to meeting the strong customer demand for services in this area while continuing to offer our customers a broad range of solutions that fit the way they want to work today - whether it be via a functional or full-service outsourcing model or both.”
Delivery of INC’s Investigator Payment FSP services will be provided through a dedicated business unit led by Victoria Moore, Vice President, Investigator Payments, with hub locations in Raleigh, NC, US; Camberley, UK; and Gurgaon, India. The Company currently is providing Investigator Payment services for several large customers under both the FSP and full-service models. INC is leveraging the Medidata Payments Cloud, the only global site payment technology driven by an integrated Electronic Data Capture (EDC) and Clinical Trial Management System (CTMS), as the foundation for its offering. Medidata Payments automates the clinical site payment workflow, processing high volumes of invoices and complex payment requests quickly and accurately.
Streamlined, on-time, global investigator payments traditionally have been overlooked in the CRO industry as many specialized investigator payment providers lack the resources, technology and global payment execution. Leveraging the insights gained from its strong site relationships across the globe, INC was able to further improve its own processing of investigator payments and in turn offer improved and streamlined investigator payment processing solutions to customers.
Functional service provision has become an increasing and important model to biopharmaceutical customers worldwide for outsourcing of clinical development services. Services typically outsourced under an FSP model include high-volume clinical development tasks that are repetitive and duplicated across many projects. INC Research offers customized FSP solutions to customers, including tactical outsourcing of certain functions on a specific trial as well as strategic outsourcing of an entire department or function such as investigator payment processing. The Company's FSP model uses strategic commitment and performance-based measures to improve productivity in key service areas. The end result is greater cost predictability and quality delivery of consistent services.
About INC Research
INC Research is a leading global contract research organization ("CRO") providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries. For more information, please visit www.incresearch.com and connect with us on LinkedIn and Twitter @INC_Research.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.